Tweet
<img alt="" height="1" width="1" />
XenoPort Tumbles in Stock Trading After Migraine Medicine Fails in Study
Bloomberg
XenoPort Inc. tumbled the most in almost five months after an experimental migraine drug it makes with GlaxoSmithKline Plc failed to help patients in a study. XenoPort fell $2.32, or 26 percent, to $6.56 at 10:19 am New ...
GSK, Xenoport drug migraine candidate failsBusinessWeek
GlaxoSmithKline likely to give up on migraine drug after failed phase II trialTriangle Business Journal
XenoPort, Glaxo Migrane Drug Fails To Outperform PlaceboWall Street Journal
FierceBiotech -RTT News -Reuters UK
all 50 news articles »
More...